Skip to main content
Top
Published in: Journal of Inherited Metabolic Disease 1/2009

01-02-2009 | BH4 and PKU

Nutritional management of PKU with glycomacropeptide from cheese whey

Authors: D. M. Ney, S. T. Gleason, S. C. van Calcar, E. L. MacLeod, K. L. Nelson, M. R. Etzel, G. M. Rice, J. A. Wolff

Published in: Journal of Inherited Metabolic Disease | Issue 1/2009

Login to get access

Summary

Individuals with phenylketonuria (PKU) must follow a lifelong low-phenylalanine (Phe) diet to prevent neurological impairment. Compliance with the low-Phe diet is often poor owing to restriction in natural foods and the requirement for consumption of a Phe-free amino acid formula or medical food. Glycomacropeptide (GMP), a natural protein produced during cheese-making, is uniquely suited to a low-Phe diet because when isolated from cheese whey it contains minimal Phe (2.5–5 mg Phe/g protein). This paper reviews progress in evaluating the safety, acceptability and efficacy of GMP in the nutritional management of PKU. A variety of foods and beverages can be made with GMP to improve the taste, variety and convenience of the PKU diet. Sensory studies in individuals with PKU demonstrate that GMP foods are acceptable alternatives to amino acid medical foods. Studies in the PKU mouse model demonstrate that GMP supplemented with limiting indispensable amino acids provides a nutritionally adequate source of protein and improves the metabolic phenotype by reducing concentrations of Phe in plasma and brain. A case report in an adult with classical PKU who followed the GMP diet for 10 weeks at home indicates safety, acceptability of GMP food products, a 13–14% reduction in blood Phe levels (p < 0.05) and improved distribution of dietary protein throughout the day compared with the amino acid diet. In summary, food products made with GMP that is supplemented with limiting indispensable amino acids provide a palatable alternative source of protein that may improve dietary compliance and metabolic control of PKU.
Literature
go back to reference Bickel H, Gerrard J, Hickmans EM (1954) The influence of phenylalanine intake on the chemistry and behavior of a phenylketonuric child. Acta Paediatr 43: 64–77.PubMedCrossRef Bickel H, Gerrard J, Hickmans EM (1954) The influence of phenylalanine intake on the chemistry and behavior of a phenylketonuric child. Acta Paediatr 43: 64–77.PubMedCrossRef
go back to reference Brody EP (2000) Biological activities of bovine glycomacropeptide. Br J Nutr 84(Supplement 1): S39–S46.PubMed Brody EP (2000) Biological activities of bovine glycomacropeptide. Br J Nutr 84(Supplement 1): S39–S46.PubMed
go back to reference Bruck WM, Redgrave M, Tuohy KM, et al (2006) Effects of bovine alpha-lactalbumin and casein glycomacropeptide-enriched infant formulae on faecal microbiota in healthy term infants. J Pediatr Gastroenterol Nutr 43: 673–679.PubMedCrossRef Bruck WM, Redgrave M, Tuohy KM, et al (2006) Effects of bovine alpha-lactalbumin and casein glycomacropeptide-enriched infant formulae on faecal microbiota in healthy term infants. J Pediatr Gastroenterol Nutr 43: 673–679.PubMedCrossRef
go back to reference Donlon J, Levy H, Scriver C (2007) Chapter 77: Hyperphenylalaninemia: phenylalanine hydroxylase deficiency. In: Scriver, C, Beaudet A, Sly W, Valle D, eds. Metabolic and Molecular Basis of Inherited Disease. New York: McGraw-Hill. http://www.ommbid.com. Donlon J, Levy H, Scriver C (2007) Chapter 77: Hyperphenylalaninemia: phenylalanine hydroxylase deficiency. In: Scriver, C, Beaudet A, Sly W, Valle D, eds. Metabolic and Molecular Basis of Inherited Disease. New York: McGraw-Hill. http://​www.​ommbid.​com.
go back to reference Etzel MR (2004) Manufacture and use of dairy protein fractions. J Nutr 134: 996S–1002S.PubMed Etzel MR (2004) Manufacture and use of dairy protein fractions. J Nutr 134: 996S–1002S.PubMed
go back to reference Gregory CO, Yu C, Singh RH (2007) Blood phenylalanine monitoring for dietary compliance among patients with phenylketonuria: comparison of methods. Genet Med 9: 761–765.PubMedCrossRef Gregory CO, Yu C, Singh RH (2007) Blood phenylalanine monitoring for dietary compliance among patients with phenylketonuria: comparison of methods. Genet Med 9: 761–765.PubMedCrossRef
go back to reference Guttler F, Azen C, Guldberg P, et al (1999) Relationship among genotype, biochemical phenotype, and cognitive performance in females with phenylalanine hydroxylase deficiency: report from the Maternal Phenylketonuria Collaborative Study. Pediatrics 104: 258–262. doi:10.1542/peds.104.2.258.PubMedCrossRef Guttler F, Azen C, Guldberg P, et al (1999) Relationship among genotype, biochemical phenotype, and cognitive performance in females with phenylalanine hydroxylase deficiency: report from the Maternal Phenylketonuria Collaborative Study. Pediatrics 104: 258–262. doi:10.​1542/​peds.​104.​2.​258.PubMedCrossRef
go back to reference Harper AE, Benevenga NJ, Wohlhueter RM (1970) Effects of ingestion of disproportionate amounts of amino acids. Physiol Rev 50: 428–439.PubMedCrossRef Harper AE, Benevenga NJ, Wohlhueter RM (1970) Effects of ingestion of disproportionate amounts of amino acids. Physiol Rev 50: 428–439.PubMedCrossRef
go back to reference IOM (2002) Dietary Reference Intakes for Energy, Carbohydrates, Fiber, Fat, Protein and Amino Acids (Macronutrients). Washington, DC: National Academy Press. IOM (2002) Dietary Reference Intakes for Energy, Carbohydrates, Fiber, Fat, Protein and Amino Acids (Macronutrients). Washington, DC: National Academy Press.
go back to reference Keogh JB, Clifton P (2008) The effect of meal replacements high in glycomacropeptide on weight loss and markers of cardiovascular disease risk. Am J Clin Nutr 87: 1602–1605.PubMed Keogh JB, Clifton P (2008) The effect of meal replacements high in glycomacropeptide on weight loss and markers of cardiovascular disease risk. Am J Clin Nutr 87: 1602–1605.PubMed
go back to reference MacDonald A, Rylance G, Davies P, Asplin D, Hall SK, Booth IW (2003) Administration of protein substitute and quality of control in phenylketonuria: a randomized study. J Inherit Metab Dis 26: 319–326. doi:10.1023/A:1025186217369.PubMedCrossRef MacDonald A, Rylance G, Davies P, Asplin D, Hall SK, Booth IW (2003) Administration of protein substitute and quality of control in phenylketonuria: a randomized study. J Inherit Metab Dis 26: 319–326. doi:10.​1023/​A:​1025186217369.PubMedCrossRef
go back to reference Matalon R, Surendran S, Matalon KM, et al (2003) Future role of large neutral amino acids in transport of phenylalanine into the brain. Pediatrics 112: 1570–1574.PubMed Matalon R, Surendran S, Matalon KM, et al (2003) Future role of large neutral amino acids in transport of phenylalanine into the brain. Pediatrics 112: 1570–1574.PubMed
go back to reference Moats RA, Moseley KD, Koch R, Nelson M Jr (2003) Brain phenylalanine concentrations in phenylketonuria: research and treatment of adults. Pediatrics 112: 1575–1579.PubMed Moats RA, Moseley KD, Koch R, Nelson M Jr (2003) Brain phenylalanine concentrations in phenylketonuria: research and treatment of adults. Pediatrics 112: 1575–1579.PubMed
go back to reference Ney DM, Hull AK, van Calcar SC, Liu X, Etzel MR (2008) Dietary glycomacropeptide supports growth and reduces the concentrations of phenylalanine in plasma and brain in a murine model of phenylketonuria. J Nutr 138: 316–322.PubMedCrossRef Ney DM, Hull AK, van Calcar SC, Liu X, Etzel MR (2008) Dietary glycomacropeptide supports growth and reduces the concentrations of phenylalanine in plasma and brain in a murine model of phenylketonuria. J Nutr 138: 316–322.PubMedCrossRef
go back to reference NIH (2000) Phenylketonuria (PKU): screening and management. NIH Consensus Statement 17: 1–33. NIH (2000) Phenylketonuria (PKU): screening and management. NIH Consensus Statement 17: 1–33.
go back to reference Pietz J, Kreis R, Rupp A, et al (1999) Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. J Clin Invest 103: 1169–1178. doi:10.1172/JCI5017.PubMedCrossRef Pietz J, Kreis R, Rupp A, et al (1999) Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. J Clin Invest 103: 1169–1178. doi:10.​1172/​JCI5017.PubMedCrossRef
go back to reference Rashed MS, Ozand PT, Bucknall MP, Little D (1995) Diagnosis of inborn errors of metabolism from blood spots by acylcarnitines and amino acids profiling using automated electrospray tandem mass spectrometry. Pediatr Res 38: 324–331. Rashed MS, Ozand PT, Bucknall MP, Little D (1995) Diagnosis of inborn errors of metabolism from blood spots by acylcarnitines and amino acids profiling using automated electrospray tandem mass spectrometry. Pediatr Res 38: 324–331.
go back to reference Slocum RH, Cummings JG (1991) Amino acid anaylsis of physiological samples. In Hommes, FA, ed. Techniques in Diagnostic Human Biochemical Genetics: A Laboratory Manual. New York: Wiley-Liss, 87–126 Slocum RH, Cummings JG (1991) Amino acid anaylsis of physiological samples. In Hommes, FA, ed. Techniques in Diagnostic Human Biochemical Genetics: A Laboratory Manual. New York: Wiley-Liss, 87–126
go back to reference Walter JH, White FJ (2004) Blood phenylalanine control in adolescents with phenylketonuria. Int J Adolesc Med Health 16: 41–45.PubMed Walter JH, White FJ (2004) Blood phenylalanine control in adolescents with phenylketonuria. Int J Adolesc Med Health 16: 41–45.PubMed
go back to reference Zhao XH, Wen ZM, Meredith CN, Matthews DE, Bier DM, Young VR (1986) Threonine kinetics at graded threonine intakes in young men. Am J Clin Nutr 43: 795–802.PubMed Zhao XH, Wen ZM, Meredith CN, Matthews DE, Bier DM, Young VR (1986) Threonine kinetics at graded threonine intakes in young men. Am J Clin Nutr 43: 795–802.PubMed
Metadata
Title
Nutritional management of PKU with glycomacropeptide from cheese whey
Authors
D. M. Ney
S. T. Gleason
S. C. van Calcar
E. L. MacLeod
K. L. Nelson
M. R. Etzel
G. M. Rice
J. A. Wolff
Publication date
01-02-2009
Publisher
Springer Netherlands
Published in
Journal of Inherited Metabolic Disease / Issue 1/2009
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-008-0952-4

Other articles of this Issue 1/2009

Journal of Inherited Metabolic Disease 1/2009 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.